莎普爱思子公司获得盐酸毛果芸香碱滴眼液临床试验批准通知书

Core Viewpoint - The company has received approval from the National Medical Products Administration for clinical trials of a new eye drop product aimed at treating presbyopia in adults [1] Group 1: Company Developments - The company's wholly-owned subsidiary, Zhejiang Shapu Health Management Co., Ltd., has obtained the clinical trial approval notice for the drug, with the notice number 2025LP02246 [1] - The company plans to initiate clinical trials once conditions are met [1] Group 2: Financial Investment - As of the announcement date, the total research and development investment for the pilocarpine hydrochloride eye drops project amounts to approximately 6.4457 million RMB [1]